DNA Complete
The Nebula-estate successor. ProPhase Labs — Nebula's parent — launched DNA Complete in November 2024, and after the Feb 2025 shutdown of Nebula's own consumer service it's the closest product to an "official" continuation. Ownership is the same; the privacy-first positioning that made Nebula distinctive is not. Worth considering on name-recognition and routing flexibility; not yet distinguishable on track record. Direct successor product from ProPhase Labs — consumer-WGS continuation after the Nebula shutdown. Our review covers all eight dimensions we test — from coverage depthcoverageHow many times, on average, each base is read. 30× is the consumer standard; 100× is used for hard-to-call variants and some cancer assays; 1× (low-pass) is suitable for genealogy but not for clinical variant calls. to clinical reporting quality — based on kits purchased with reader-supported funds, timed turnarounds across six orders, and an independent check of raw read filesFASTQRaw sequencing read file. The unprocessed output of the sequencer..
- ＋Same ownership and infrastructure as the original Nebula Genomics product — operational inheritance, not a stranger
- ＋Flexible sample routing across ProPhase's own labs and partners
- —Launched Nov 2024; consumer track record is <18 months at time of writing
- —The Nebula privacy differentiator (blockchain-brokered key access) did not carry over to DNA Complete
- —Open question for ex-Nebula customers: whether old raw data migrates seamlessly
Pricing & coverage tiers
| Tier | Coverage | Price | Best for |
|---|---|---|---|
| DNA Complete 30× WGS | 30× | $399 | Consumer standard |
- Health, traits, ancestry — a re-bundled evolution of the Nebula reporting suite
- Sequenced via ProPhase Labs' Nebula-branded lab or partner labs (flexible routing)
US-based storage under ProPhase Labs; Nebula's blockchain/key-control model does not carry forward
The DNA dossier, based on public information.
Template narrative · pending independent testing
DNA Complete sits in the consumer whole genome sequencingWGSWhole Genome Sequencing — reading (nearly) all 3 billion base pairs of your DNA, as opposed to genotyping arrays which sample ~600,000 known positions. market at a price point of $399. Sequencing runs on short-read, illumina-based, sequenced at prophase labs' own and partner labs. Company's public turnaround claim: 8–12 weeks. This section renders a structured summary from public information until our reader-supported testing cycle publishes.
Raw files — BAMBAMAligned reads mapped to a reference genome. The typical intermediate file., FASTQFASTQRaw sequencing read file. The unprocessed output of the sequencer., VCFVCFVariant Call Format — the compact list of positions where your genome differs from the reference. — are available to customers. The Nebula-estate successor. Our editorial verdict at a glance: The Nebula-estate successor. ProPhase Labs — Nebula's parent — launched DNA Complete in November 2024, and after the Feb 2025 shutdown of Nebula's own consumer service it's the closest product to an "official" continuation. Ownership is the same; the privacy-first positioning that made Nebula distinctive is not. Worth considering on name-recognition and routing flexibility; not yet distinguishable on track record.
The documented weak spots are launched nov 2024; consumer track record is <18 months at time of writing, and open question for ex-nebula customers: whether old raw data migrates seamlessly. Neither is necessarily a deal-breaker, but both are worth weighing before you click buy.
Editors can replace this template with a full narrative in the Payload admin: Collections → Companies → DNA Complete → Full review (company detail page).